Anti lamin a c antibody

Human embryonic kidney cell HEK293T, hepatic carcinoma cell HepG2, human lung carcinoma cell A549, and human colorectal adenocarcinoma Caco-2 were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, Logan, UT) containing 10% inactivated fetal bovine serum (BBI, Shanghai, China), penicillin (100 IU/ml), and streptomycin (100 mg/ml) at 37 °C in a 5% CO₂ atmosphere. Sg25 cell is derived from HepG2 cell, in which TRIM25 has been knocked out through the CRISPR/Cas9 system.^{45 (link)}Antibodies against STAT1, p-STAT1, and STAT2 were purchased from Abcam (Cambridge, MA, USA); anti-IRF3, anti-TBK1, anti-HA, anti-GST, anti-Flag, anti-GAPDH, CoraLite 594-conjugated IgG, and CoraLite 488-conjugated IgG secondary antibodies were obtained from Proteintech (Rosemont, IL, USA); anti-TRIM25, anti-IKKε, anti-pIKKε, anti-pTBK1, and anti-pIRF3 antibodies were from Cell Signaling technology (Danvers, MA, USA); anti-pSTAT2 antibody was from Sigma-Aldrich (St. Louis, MO, USA); anti-Lamin A/C antibody was from TransGen (Beijing, China); anti-SeV antibody was from MBL (Beijing, China); Human anti-SARS-CoV & CoV-2 NP antibody was from ZENBIO (Chengdu, China).

TBEV structural and nonstructural proteins (GenBank Access Number MN615726.1), DENV2 (NC_001474), JEV (NC_001437.1), YFV(NC_002031.1), WNV(NC_001563.2), ZIKV (NC_012532.1) prM genes or TBEV prM truncations were cloned into Flag-VR1012 at Sangon Biotech (Shanghai, China). The expression plasmids of IFN-β-Luc reporter, ISRE-Luc reporter, Renilla-Luc, RIG-I, MDA5, TBK1, IKKε, IRF3 and TRAF3 were constructed in our previous study [49 (link)]. The NF-κB-Luc and MAVS plasmids were purchased from Miaoling Biotech (Wuhan, China). Anti-HA, anti-GST, anti-Flag, anti-Myc, anti-GAPDH, anti-Actin CoraLite 594-conjugated IgG, and CoraLite 488-conjugated IgG secondary antibodies were obtained from Proteintech (Wuhan, China); anti-Lamin A/C antibody from TransGen (Beijing, China); anti-Phospho-IRF3 (S396) and anti-Phospho-TBK1 antibodies from Cell Signaling technology (Danvers, USA); and anti-SeV antibody from MBL (Beijing, China).